MARKET

XENE

XENE

Xenon Pharmaceut
NASDAQ
31.42
-0.42
-1.30%
Opening 15:05 07/08 EDT
OPEN
31.83
PREV CLOSE
31.83
HIGH
32.24
LOW
31.39
VOLUME
533.47K
TURNOVER
--
52 WEEK HIGH
46.00
52 WEEK LOW
26.74
MARKET CAP
2.41B
P/E (TTM)
-9.7674
1D
5D
1M
3M
1Y
5Y
1D
Citizens JMP pharmaceuticals analysts hold analyst/industry conference call
TipRanks · 1d ago
Weekly Report: what happened at XENE last week (0630-0704)?
Weekly Report · 1d ago
Xenon Appoints CEO Ian Mortimer as Interim CFO
TipRanks · 5d ago
XENON PHARMACEUTICALS INC - SHERRY AULIN RESIGNS AS XENON'S CFO - SEC FILING
Reuters · 5d ago
FDA flags possible safety signals in new report, says RBC Capital
TipRanks · 06/30 15:50
Weekly Report: what happened at XENE last week (0623-0627)?
Weekly Report · 06/30 10:19
Optimistic Buy Rating for Xenon Pharmaceuticals Driven by Promising Phase 2 Results of Azetukalner
TipRanks · 06/30 10:16
Xenon Pharmaceuticals joins Russell 3000, Russell 2000 Indexes
TipRanks · 06/27 20:05
More
About XENE
Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.

Webull offers Xenon Pharmaceuticals Inc stock information, including NASDAQ: XENE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XENE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XENE stock methods without spending real money on the virtual paper trading platform.